Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 11/20 | 0.71 |
| ▸ | FNTB | P49356 | 11/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724627 | 1.00 | FNTA (0.71) | FNTAFNTBKDM4EATMMAPT | |
| SCHEMBL1724630 | 1.00 | FNTA (0.71) | FNTAFNTBKDM4EATMMAPT | |
| SCHEMBL29054431 | 1.00 | FNTA (0.71) | FNTAFNTBKDM4EATMMAPT | |
| SCHEMBL29054449 | 0.87 | FNTA (0.72) | FNTAFNTBKDM4EATMMAPT | |
| SCHEMBL29054448 | 0.87 | FNTA (0.72) | FNTAFNTBKDM4EATMMAPT | |
| SCHEMBL15296278 | 0.87 | FNTA (0.72) | FNTAFNTBKDM4EATMMAPT | |
| SCHEMBL15298847 | 0.85 | FNTA (0.94) | FNTAFNTBKDM4EATMMAPT | |
| SCHEMBL29054446 | 0.85 | FNTA (0.94) | FNTAFNTBKDM4EATMMAPT | |
| SCHEMBL29054447 | 0.85 | FNTA (0.94) | FNTAFNTBKDM4EATMMAPT | |
| SCHEMBL20335742 | 0.84 | FNTA (0.69) | FNTAFNTBKDM4EATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399900-B1 | Geranyl compounds | OHGEN RES LAB LTD (JP) | 2013-08-07 | — | — | EP | disclosed |
| EP-2404894-A1 | Mevalonic Acid Derivatives | Ohgen Research Laboratories Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| EP-2399899-A1 | Geranyl compounds | Ohgen Research Laboratories Ltd. (JP) | 2011-12-28 | — | — | EP | disclosed |
| EP-2399900-A1 | Geranyl compounds | Ohgen Research Laboratories Ltd. (JP) | 2011-12-28 | — | — | EP | disclosed |
| US-7579376-B2 | N-geranoyltyrosine and N-geranoylcycteine as excellant antitumor and anticarcinogenic agents | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2009-08-25 | — | — | US | disclosed |
| US-7553820-B2 | Mevalonic acid derivatives | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7507765-B2 | Geranyl compounds | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20080119556-A1 | Geranly compounds | AKIYAMA KIYOSHI | 2008-05-22 | — | — | US | disclosed |
| US-20080113939-A1 | Geranyl compounds | AKIYAMA KIYOSHI | 2008-05-15 | — | — | US | disclosed |
| US-7125852-B2 | Geranyl compounds | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060142244-A1 | Geranyl compounds | AKIYAMA KIYOSHI | 2006-06-29 | — | — | US | disclosed |
| US-20050119474-A1 | Geranyl compounds | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1471052-A1 | GERANYL COMPOUNDS | Ohgen Research Laboratories Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113939-A1 | Geranyl compounds | GGPS1, FNTA, CCNE2 | FNTA 2/4885FNTB 64/4885KDM4E 1675/4885 |
| US-20080119556-A1 | Geranly compounds | GMNN, TP53, MCL1 | FNTA 406/4885FNTB 1727/4885KDM4E 1492/4885 |
| US-20060142244-A1 | Geranyl compounds | GGPS1, FNTA, CCNE2 | FNTA 2/4885FNTB 64/4885KDM4E 1675/4885 |
| US-20050119474-A1 | Geranyl compounds | GGPS1, FNTA, CCNE2 | FNTA 2/4885FNTB 64/4885KDM4E 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.